Our team is comprised of scientists and industry leaders who are not only experts at their craft, but are creatives who think outside the box. Together with our world-class scientific advisors, we are both driven and well-positioned to overcome the hurdles ahead of us to bring impactful new therapies to patients in need.
The Remix Team
Peter Smith, PHD
Co-Founder, President and Chief Scientific Officer
Pete is Co-Founder, President and CSO of Remix Therapeutics. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Pete received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Heather Wasserman, PhD
Chief Operating Officer, Chief Business Officer
Heather is responsible for corporate business development and operations at Remix. She joins after 7 years at Eli Lilly, where she gained extensive business knowledge while heading up immunology search and evaluation, emerging technologies and innovations and most recently global corporate business development during her tenure there. Heather received a PhD from the University of Georgia, and went on to complete a postdoctoral fellowship at Emory University. Heather is excited to work alongside Remix’s talented team focused on novel small molecule modulation of RNA processing.
Jesse Smith, PhD
Senior Vice President, Biology and Translational Sciences
Jesse works to define strategies for progression of Remix pipeline programs while vetting new target opportunities. Jesse has held numerous leadership positions in the biotech and pharmaceutical spaces. As VP of Biology at Epizyme Pharmaceuticals, his team advanced to the clinic the first EZH2 inhibitor, which was recently approved in two oncology indications. He received his PhD in Molecular Cancer Biology from Duke University Medical Center and was a postdoctoral fellow at the National Cancer Institute.
Dominic Reynolds, PhD
Senior Vice President, Chemistry
As head of chemistry, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds to reprogram RNA processing and forge a path to the clinic. Dominic has extensive experience in the biotech space and building successful biotech companies. Recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.
Mike Seiler, PhD
Sr. Director, Bioinformatics and Data Science
Heading up computational biology, Michael brings a passion for RNA biology and processing to the Remix team. He joins with notable computational biology experience in the biotech space, most recently serving as head of computational biology at Arrakis Therapeutics and prior to that as a computational scientist leading splicing bioinformatics efforts at H3 Biomedicine. Michael completed his PhD in computational biology and molecular biophysics at Rutgers University and is excited to utilize his experience in further building a platform to harness powerful RNA processing to impact patients’ lives.
Fred Vaillancourt, PhD
Vice President, Biomolecular Sciences and Lead Discovery
Fred oversees the biomolecular sciences, screening and lead discovery effort at Remix Therapeutics. He joins the team with more than 15 years of experience in a range of roles in drug discovery, most recently serving as a consultant for Third Rock Ventures. Prior to that, Fred held various leadership roles at H3 Biomedicine and Boehringer Ingelheim. Now, Fred is motivated to push the current boundaries of drug discovery with the Remix team. He received his PhD in biochemistry and molecular biology from the University of British Columbia and completed his postdoctoral training as a Merck-sponsored Helen Hay Whitney Foundation fellow at Harvard Medical School.
Board Of Directors
Scott Biller, PhD
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Kevin Bitterman, PhD
Partner, Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Managing Director, Arch Venture, Board Observer
In her role as Managing Director at Arch Venture, Kristina is focused on the creation and development of biotechnology, pharmaceutical and health tech companies. Since joining ARCH in 2002, she has played a significant role in the growth of ARCH’s life sciences portfolio, including multiple public companies exceeding billion dollar valuations.
Kristina is a Director of Beam Therapeutics (BEAM), Vividion Therapeutics, RBNC, Gossamer Bio (GOSS), Metacrine (MTCR), Scholar Rock (SRRK), Unity Biotechnology (UBX), Boundless Bio, Autobahn Therapeutics, ROME Therapeutics, Boragen and AgBiome. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene) and was a Director of VIR Biotechnology (VIR), Epirium Bio and BlackThorn Therapeutics. Kristina has participated and led investments in a number of other ARCH portfolio companies including Erasca, Dewpoint, Therapeutics, Mindstrong, Aledade, Kura Oncology (KURA), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), and Ikaria (acquired by Mallinckrodt).
Leon Chen, PhD
Partner, The Column Group
Leon is currently a Partner at The Column Group, a healthcare venture capital firm. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx, and Adicet. He also served on the board of directors of Pionyr Immunotherapeutics and Logic Bio. Prior to that Leon was a Partner at Skyline Ventures and an entrepreneur in residence at Venrock. Leon started his career in 2002 as a founder of KAI Pharmaceuticals, which was acquired by Amgen in 2012 and led to the approval of Parsabiv in the US, Europe, and Japan. He holds a PhD in molecular pharmacology from Stanford School of Medicine, and an MBA from Stanford Graduate School of Business.
Matt is a biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. He is currently serving in the role of Strategic Advisor to Audentes Therapeutics after co-founding and leading the company from 2013 until its sale to Astellas in 2020. Prior to Audentes, Matt was an Entrepreneur-In-Residence with OrbiMed and held senior roles at Amicus Therapeutics, BioMarin Pharmaceutical. and Genzyme Corporation. He serves on several boards, including Homology Medicines, Inc., Vor Biopharma, Inc., 5:01 Acquisition Corporation, and the Alliance for Regenerative Medicine (ARM).
Michael Rome, PhD
Managing Director, Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Peter Smith, PhD
President and CSO
Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Angela Brooks, PHD
University of California Santa Cruz
Christopher Burge, PHD
Massachusetts Institute of Technology
Benoit Chabot, PHD
University of Sherbrooke Canada
Ryan Corcoran, MD, PhD
MGH Cancer Center and Harvard Medical School
Will Fairbrother, PHD
Aaron Hoskins, PHD
University of Wisconsin
Juan Valcarcel, PHD
Center for Genomic Regulation, Barcelona
Rui Zhao, PHD
University of Colorado